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ABSTRACT
6\VWHPLF/XSXV(U\WKHPDWRXV6/(LVDFKURQLFLQÀDPPDWRU\GLVHDVHWKDWDIIHFWDOPRVWDQ\RUJDQV\VWHP
Patient with SLE is at risk of osteoporosis. Biphosphonate is one of osteoporosis treatments. However, esophageal 
VWULFWXUH(6FDXVHGE\FRQWLQXRXVHVRSKDJHDOLQÀDPPDWLRQDVDUHVXOWRIORQJWHUPXVH%LSKRVSKRQDWHFDQ
RFFXU,QWUDOHVLRQ7ULDPFLQRORQH,QMHFWLRQ,7,EHFRPHVRQHRI(6WKHUDS\E\LQKLELWLQJLQÀDPPDWRU\UHVSRQVH
to injury and decrease subsequent collagen formation. ITI inhibits transcription of matrix protein genes, including 
¿EURQHFWLQDQGSURFROODJHQ ,WDOVR UHGXFHV WKH V\QWKHVLVRIĮPDFURJOREXOLQDQ LQKLELWRURI FROODJHQDVH
activity. A 43 year old woman was diagnosed with SLE. She was treated with Risedronic Acid (bisphosphonate 
FODVVPJRQFHDZHHN$IWHUPRQWKV6KHVWDUWHGFRPSODLQLQJGLI¿FXOW\WRVZDOORZ6\PSWRPZDVJHWWLQJ
ZRUVHPRQWKVODWHU2QHWKLUGGLVWDO(6ZLWKLQÀDPPDWLRQSURFHVVZDVIRXQGZLWKHQGRVFRS\,7,PJZDV
JLYHQLQLQÀDPPDWLRQDUHD6KHZDVVFKHGXOHGWRIROORZXSDIWHUGD\VIRUUHHQGRVFRS\(QGRVFRS\VKRZHG
WKDWLQÀDPPDWLRQSURFHVVKDGEHHQLPSURYHG6L[PRQWKVODWHUVKHKDGDJDLQFRPSODLQHGGLI¿FXOW\WRVZDOORZ
DQGZHIRXQGWKDWVKHVWLOOFRQVXPHG5LVHGRQLF$FLG,7,PJZDVJLYHQEHFDXVHLQÀDPPDWLRQDQG(6ZDV
IRXQGZLWKHQGRVFRS\$IWHUGD\VHQGRVFRS\VKRZHGWKDWWKHUHZDVQR(6DQGLQÀDPPDWLRQSURFHVVKDGEHHQ
improved. She was advised to stop Risedronic Acid consumption.
Keywords: Intralesion Triamcinolone injection, esophageal stricture, systemic lupus erythematous (SLE), 
Biphosphonate
ABSTRAK
6LVWHPLNOXSXVHULWHPDWXV6/(DGDODKSHQ\DNLWLQÀDPDVLNURQLN\DQJEHUHIHNSDGDKDPSLUVHPXDVLVWHPRUJDQ
Pasien dengan SLE beresiko osteoporosis. Biposponat adalah salah satu pengobatan osteoporosis. Striktur esofagus 
(SE) dapat terjadi disebabkan oleh peradangan esofagus hasil dari penggunaan Biposponat jangka panjang. 
,QMHNVL7ULDPVLQRORQ ,QWUDOHVL ,7,PHQMDGL VDODKVDWXSHQJREDWDQ6(GHQJDQPHQJKDPEDW UHVSRQ LQÀDPDVL
terhadap cedera dan menurunkan pembentukan kolagen. ITI menghambat transkripsi gen matriks protein yang 
WHUGLULDWDV¿EURQHNWLQGDQSURNRODJHQ,7,MXJDPHQXUXQNDQVLVWHVLVĮPDFURJOREXOLQSHQJKDPEDWDNWLYLWDV
kolagenase. Pasien wanita 43 tahun didiagnosis dengan SLE. Pasien tersebut diberikan Asam Risedonat (golongan 
%LSRVSRQDWPJVHNDOLVHPLQJJX6HWHODKEXODQSDVLHQPHQJHOXKNDQNHVXOLWDQPHQHODQ*HMDODPHPEXUXN
EXODQNHPXGLDQ6HSHUWLJDGLVWDO6(GHQJDQSURVHVLQÀDPDVLGLWHPXNDQPHODOXLHQGRVNRSL,7,PJGLEHULNDQ
SDGDGDHUDKLQÀDPDVL3DVLHQGLMDGZDONDQXQWXNGDWDQJKDULNHPXGLDQXQWXNHQGRVNRSLNHPEDOL(QGRVNRSL
PHQXQMXNNDQSURVHVLQÀDPDVLPHPEDLN(QDPEXODQNHPXGLDQSDVLHQNHPEDOLPHQJHOXKNDQNHVXOLWDQPHQHODQ
GDQGLNHWDKXLSDVLHQPDVLKPHQJNRQVXPVLDVDPULVHGRQDW,7,PJNHPEDOLGLEHULNDQNDUHQD6(GLWHPXNDQ
SDGDHQGRVNRSL6HWHODKKDULNHPXGLDQKDVLOHQGRVNRSLPHQXQMXNNDQWLGDNDGDODJL6(GDQSURVHVLQÀDPDVL
membaik. Pasien kemudian disarankan untuk berhenti mengkonsumsi asam risedonat.
Kata kunci: injeksi Triamsinolon intralesi, striktur esofagus, SLE, Biposponat
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INTRODUCTION
Systemic Lupus Erythematous (SLE) is a chronic 
inflammatory disease that can affect almost any 
organ system. More than 90% of cases of SLE, occur 
in woman, frequently starting at childbearing age. 
Patient with SLE is at risk of osteoporosis through 
VHYHUDO IDFWRUV WKH LQÀDPPDWRU\ GLVHDVH LWVHOI DQG
disease related to comorbidity and its treatment (such 
as corticosteroid). Biphosphonate is one of class 
agents used to treat osteoporosis which inhibits bone 
resorption that is impacting bone mineral density 
increase. However, bisphosphonate is a local irritant 
to the gastrointestinal tract and esophagitis. Moreover, 
esophageal stricture was reported as side effect of 
bisphosphonate. As triamcinolone has inhibitory effect 
RQ LQÀDPPDWRU\ SURFHVV DQG GHFUHDVH VXEVHTXHQW
collagen formation, triamcinolone to treat esophageal 
stricture has been applied.
CASE ILLUSTRATION
A 43 year old woman was diagnosed with SLE 
and due to osteoporosis, She was treated with 
Risedronic Acid (bisphosphonate group) 35 mg once 
a week. After 8 months of treatment, She started 
FRPSODLQLQJGLI¿FXOW\WRVZDOORZ7KHUHLVQRKLVWRU\
of tobacco, alcohol and NSAID use before and she was 
hemodynamically stable. 6 months later, the symptom 
was getting worse and one-third distal esophagus 
VWULFWXUHZLWK LQÀDPPDWLRQSURFHVVZDV IRXQGZLWK
endoscopy. Intralesion triamcinolone injection 150 mg 
ZDVJLYHQLQLQÀDPPDWLRQDUHD6KHZDVVFKHGXOHGWR
follow up after 7 days for re-endoscopy. The endoscopy 
)LJXUH(QGRVFRS\ UHVXOW 'HFHPEHURQH WKLUGGLVWDOHVRSKDJHDOVWULFWXUHZLWK
LQÀDPPDWLRQSURFHVV OHIW )LUVW LQWUDOHVLRQ WULDPFLQRORQH LQMHFWLRQZDVJLYHQ PLGGOH
LQÀDPPDWLRQKDGEHHQLPSURYHGULJKW
)LJXUH(QGRVFRS\UHVXOW0D\RQHWKLUGGLVWDOHVRSKDJHDOVWULFWXUHZLWKLQÀDPPDWLRQ
SURFHVV OHIW VHFRQG LQWUDOHVLRQ WULDPFLQRORQH LQMHFWLRQZDVJLYHQ PLGGOH WKHUH LVQR
VWULFWXUHDQGLQÀDPPDWLRQKDGEHHQLPSURYHGULJKW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results after the re-examination showed that the 
LQÀDPPDWLRQSURFHVVLQHVRSKDJXVZDVJHWWLQJEHWWHU
with triamcinolone injection. 
Six months later, she had again complained 
difficulty to swallow and we found that she still 
consumed Risedonic Acid. Intralesion Triamcinolone 
,QMHFWLRQPJZDVJLYHQEHFDXVHLQÀDPPDWLRQDQG
Esophageal stricture was found with endoscopy. After 
7 days, endoscopy showed that there was no stricture 
HVRSKDJHDOIRXQGDQGLQÀDPPDWLRQSURFHVVKDGEHHQ
improved. She was advised to stop Risedronic Acid 
consumption.
DISCUSSION
Osteoporosis is a systemic skeletal disorder 
characterised by low bone mass and microarchitectural 
deterioration of bone tissue, with a consequent increase 
in bone fragility and susceptibility to fracture. Etiology 
of osteoporosis in SLE patient are disease activity, 
reduced sunlight exposure that result abnormal vitamin 
D metabolism, and glucocorticoids and cytotoxic drugs 
for treatment ovarian dysfuction may have detrimental 
effect on bone mineral density.1
Bisphosphonate is used as osteoporosis treatment. 
Bisphosphonate increases bone density by selectively 
suppress osteoclast activity with relative preservation 
(at least initially) of osteoblast activity. However, 
because of there is GIT site effect, the use of 
bisphosphonate must be thorough. The association 
between bisphosphonate and esophageal may result 
in adverse effects such as acute esophagitis caused 
by direct contact of drug with esophageal mucosa. 
Esophageal stricture caused by continuous esophageal 
LQÀDPPDWLRQDVDUHVXOWRIORQJWHUPXVHFDQDOVREH
occurred.2,3,4
Biphosphonate attenuated the hidrophobic surface 
barier of the stomach, which normally protects the 
mucosa from injury by luminal acid and thereby 
cause mucosal injury. Phosphatidylcholine is one of 
the phospholipids responsible for the hydrophobic 
properties of the bilayer. Phosphatidylcholine 
has demonstrated an ability to protect GI cells 
from irritating agents. Both bisphosphonates and 
Phosphatidylcholine are similar in size and molecular 
structures. When bisphosphonates bind, this prevents 
Phosphatidylcholine or other protective phospholipids 
from binding and producing the hydrophobic barrier 
that protects the epithelial lining from gastric acid.5
Esophageal stricture form as the result of injury 
of esophageal wall with the subsequent development 
of scar tisuue and secondary tissue contraction. The 
pathogenesis of all benign esophageal strictures except 
congenital stricture is transmural cellular injury; the 
LQÀDPPDWLRQWKDWHQVXHVOHDGVWRFROODJHQGHSRVLWLRQ
DQG¿EURVLVDQGXOWLPDWHO\FDXVHDFLFDWULFLDOQDUURZLQJ
of the lumen. Treatment strategies of benigm stricture 
is to: (1) Establish patency of esophageal lumen; (2) 
'LVUXSWDQGGLVSODFH WKH¿EURWLF WLVXXHRI VWULFWXUHV
)LJXUH7UHDWPHQW$OJRULWKPRI(VRSKDJHDO6WULFWXUH6LHUVHPD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to restrore a satisfactory diameter of the lumen; (3) 
0LQLPL]H RU SUHYHQW UHRUJDQL]DWLRQ RI WKH ¿EURWLF
tissue; (4) Minimize or prevent ongoing cellular injury.6
Treatment of esophageal strictures aims to 
relieve symptoms of dysphagia, with avoidance of 
complications and prevention of recurrences. The 
¿UVWVWHSLQPDQDJLQJDEHQLJQHVRSKDJHDOVWULFWXUHLV
balloon or Savary-Gilliard dilation, preferably to 16 
mm or to 18 mm . The recommendation to perform 
at least 5 dilations to the maximum diameter before 
deciding to switch to an alternative treatment is usually 
attempted. this treatment management is recommended 
to be performed in dilation frequencies of once per 
week or even twice per week.7
After maximum dilation, the next step in the 
management of a refractory benign esophageal stricture 
is to combine dilation with intralesional steroid. Adding 
steroid injection to endoscopic dilation into stricture 
has been reported to prevent stricture reccurence. Stent 
placement is a treatment option to consider when an 
adequate luminal diameter has not been established 
with previous treatment modalities or when the stricture 
still recurs within a short time interval. An alternative 
treatment option is to teach the patient self-bougienage 
using Maloney dilators. This is not a commonly 
performed practice, but self-bougienage is safe and 
HIIHFWLYHZKHQSDWLHQWVKDYHVXI¿FLHQWO\OHDUQHGWKH
technique, and this can be useful in selected patients 
who are not afraid of performing the procedure. Ballon 
Dilation is not performed in these patient as it increases 
the risk of esophageal perforation.7,8
On the basis of successful injection treatment for 
dermatologic scars such as keloids and burn scars, 
intralesional injection of corticosteroids has been 
practiced in refractory esophageal strictures of various 
etiologies for the last 40 years. It has been shown 
WKDWWULDPFLQRORQHLQKLELWVLQÀDPPDWRU\UHVSRQVHWR
injury and decrease subsequent collagen formation. 
Intralesional triamcinolon injections inhibit esophageal 
stricture formation by interfering with collagen 
V\QWKHVLV ¿EURVLV DQG FKURQLF VFDUULQJ SURFHVVHV
Triamcinolone inhibits the transcription of matrix 
SURWHLQJHQHVLQFOXGLQJ¿EURQHFWLQDQGSURFROODJHQ
,WDOVRUHGXFHVWKHV\QWKHVLVRIĮPDFURJOREXOLQDQ
inhibitor of collagenase activity. 4,9,10
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